Straits Times Index
3,306.66 +3.47 (+0.11%) Nikkei
38,675.00 +438.93 (+1.15%) Hang Seng
18,513.41 -64.89 (-0.35%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,721.39 -462.17 (-0.72%) CMC Crypto 200
1,373.43 +60.80 (+4.63%)
NGM Biopharmaceuticals Inc (0IK.MU)
- GlobeNewswire
NGM Bio Announces Closing of Tender Offer
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. (“Merger Sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of
- GlobeNewswire
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting,
- Zacks
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 10.81% and 91.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
